S&P 5007,651.54▼0.2% Nasdaq26,861.06▲0.2% Dow50,906.05▼0.9% Russell 2K2,796.86▼0.4% 10-Yr5.29%+4bp VIX16.34+0.30 WTI$90.46▲1.2% Gold$4,189.00▲0.2% EUR/USD1.133▼0.3% BTC$86,548▲3.6% Nikkei65,481▼0.6%
At close · Wed, Sep 30, 2026
Daily Market Updates.

Insurance

Home›Insurance›Industry & Deals›Investors weigh prospects for insurers covering Galler…

Investors weigh prospects for insurers covering Galleri cancer test

Reported · Written up by our desk · Industry & Deals

An FDA panel has endorsed Grail’s Galleri cancer test, but coverage economics tied to Medicare remain uncertain, according to WSJ Markets.

The financing model for the business depends heavily on reimbursement, and the source highlights that Medicare payment for the test is not yet assured.

← Newer storyCrypto market holds near $2.86T as Bitcoin slips below $85K

More like this

InsuranceHIVE Underwriters appoints Richard Brown to lead global property D&F push
InsuranceInsurers and employers add AI and workflow automation to return-to-work
InsuranceRAND finds AI losses in insurance are tied mostly to fake content
InsurancePhoenix unit sues Nationwide affiliate over Costco slip-and-fall defense costs
InsuranceAllstate sues three New York pharmacies over alleged no-fault fraud

Sources

WSJ MarketsA Cancer Test Has Investors Betting Big. But Will Insurers Pay?

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.